Oncodesign Precision Medicine
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a rad… Read more
Market Cap & Net Worth: Oncodesign Precision Medicine (ALOPM)
Oncodesign Precision Medicine (PA:ALOPM) has a market capitalization of $9.12 Million (€8.88 Million) as of March 19, 2026. Listed on the PA stock exchange, this France-based company holds position #46112 globally and #548 in its home market, demonstrating a -17.18% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oncodesign Precision Medicine's stock price €0.48 by its total outstanding shares 18426193 (18.43 Million).
Oncodesign Precision Medicine Market Cap History: 2022 to 2026
Oncodesign Precision Medicine's market capitalization history from 2022 to 2026. Data shows change from $32.15 Million to $9.12 Million (-15.17% CAGR).
Oncodesign Precision Medicine Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oncodesign Precision Medicine's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
65.23x
Oncodesign Precision Medicine's market cap is 65.23 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $32.15 Million | $7.98 Million | -$231.18K | 4.03x | N/A |
| 2023 | $34.23 Million | $1.07 Million | -$8.09 Million | 31.93x | N/A |
| 2024 | $13.50 Million | $207.04K | -$7.21 Million | 65.23x | N/A |
Competitor Companies of ALOPM by Market Capitalization
Companies near Oncodesign Precision Medicine in the global market cap rankings as of March 19, 2026.
Key companies related to Oncodesign Precision Medicine by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Oncodesign Precision Medicine Historical Marketcap From 2022 to 2026
Between 2022 and today, Oncodesign Precision Medicine's market cap moved from $32.15 Million to $ 9.12 Million, with a yearly change of -15.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €9.12 Million | +16.99% |
| 2025 | €7.79 Million | -42.30% |
| 2024 | €13.50 Million | -60.55% |
| 2023 | €34.23 Million | +6.47% |
| 2022 | €32.15 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Oncodesign Precision Medicine was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.12 Million USD |
| MoneyControl | $9.12 Million USD |
| MarketWatch | $9.12 Million USD |
| marketcap.company | $9.12 Million USD |
| Reuters | $9.12 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.